Cargando…

TTF-1 and immune checkpoint therapy in non-small cell lung cancer

Detalles Bibliográficos
Autores principales:	Gumbleton, Matthew, Snyder, Eric L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087989/ https://www.ncbi.nlm.nih.gov/pubmed/37057105 http://dx.doi.org/10.21037/tlcr-23-101

Ejemplares similares

Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer
por: Iso, Hirokazu, et al.
Publicado: (2023)

The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer
por: Hakozaki, Taiki
Publicado: (2022)

Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer
por: Uehara, Yuji, et al.
Publicado: (2022)

Comparative analysis of TTF‐1 binding DNA regions in small‐cell lung cancer and non‐small‐cell lung cancer
por: Hokari, Satoshi, et al.
Publicado: (2019)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non–small cell lung carcinoma
por: Nakra, Tripti, et al.
Publicado: (2021)

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer
por: Riess, Jonathan W., et al.
Publicado: (2016)

Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis
por: Kim, Jung Han, et al.
Publicado: (2018)

Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer
por: De Giglio, Andrea, et al.
Publicado: (2022)

Neoadjuvant immunotherapy in resectable non-small cell lung cancer at a checkpoint
por: Faltermeier, Claire M., et al.
Publicado: (2021)

Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?
por: Pirker, Robert
Publicado: (2018)

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
por: Soh, Junichi, et al.
Publicado: (2021)

Diagnostic and Prognostic Significances of MUC5B and TTF-1 Expressions in Resected Non-Small Cell Lung Cancer
por: Nagashio, Ryo, et al.
Publicado: (2015)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

Challenges of predicting immune checkpoint therapy responders in lung cancer
por: Marwitz, Sebastian
Publicado: (2019)

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
por: Liu, Xiaoming, et al.
Publicado: (2017)

Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer
por: Jiang, Jiehan, et al.
Publicado: (2021)

TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC)
por: Messaritakis, Ippokratis, et al.
Publicado: (2017)

Immune checkpoint inhibitors for non-small cell lung cancer patients on steroid or non-steroidal anti-inflammatory drugs treatment—therapeutic indication or therapeutic efficacy?
por: Kawase, Akikazu
Publicado: (2022)

Impact of Results of TTF-1 Immunostaining on Efficacy of Platinum-Doublet Chemotherapy in Japanese Patients with Nonsquamous Non-Small-Cell Lung Cancer
por: Nakao, Akira, et al.
Publicado: (2022)

Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
por: Corke, Lucy K., et al.
Publicado: (2022)

Differential Expression of PD-L1 in Central and Peripheral and TTF1-Positive and -Negative Small-Cell Lung Cancer
por: Yu, Shili, et al.
Publicado: (2021)

Advances in immune checkpoint inhibitors therapy for small cell lung cancer
por: Li, Longhui, et al.
Publicado: (2023)

Replication and Meta-Analysis of Common Gene Mutations in TTF1 and TTF2 with Papillary Thyroid Cancer
por: Gao, Yan, et al.
Publicado: (2015)

TTF Meeting
por: Edwards, D A
Publicado: (1997)

Immunocytochemical Evaluation of TTF-1, Napsin-A, and p-63 for Subtyping of Non-Small Cell Lung Carcinoma and Clinicopathological Correlation
por: Sharma, Tarun, et al.
Publicado: (2022)

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
por: Hida, Toyoaki, et al.
Publicado: (2020)

Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer
por: Yomota, Makiko, et al.
Publicado: (2021)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Wiest, Nathaniel, et al.
Publicado: (2021)

Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
por: Hendriks, Lizza E. L., et al.
Publicado: (2021)

Pneumonitis in advanced non-small cell lung cancer: no interaction between immune checkpoint inhibition and radiation therapy
por: Neibart, Shane S., et al.
Publicado: (2023)

Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Jung, Chi Young, et al.
Publicado: (2018)

Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
por: Qiu, Zhenbin, et al.
Publicado: (2019)

Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Ushio, Ryota, et al.
Publicado: (2022)

On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer
por: Correale, Pierpaolo, et al.
Publicado: (2020)

MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer
por: Sun, Lei, et al.
Publicado: (2021)

Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy
por: Dal Collo, Giada, et al.
Publicado: (2023)

Stereotactic body radiation therapy for metastatic non-small cell lung cancer: a versatile treatment, repurposed
por: Shen, James L., et al.
Publicado: (2022)

Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer
por: Misch, Daniel, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6csk0mjpm9d6muj7m08pp6b67p